IDNLearn.com is your trusted platform for finding reliable answers. Ask your questions and receive prompt, detailed answers from our experienced and knowledgeable community members.
Sagot :
A case study:
Rare but possibly blinding, severe retinal vasculitis affects people with systemic lupus erythematosus (SLE). Here, we describe the first case of severe bilateral SLE-associated retinal vasculitis that was successfully treated with the anti-CD20 monoclonal antibody rituximab. This medication has a well-established role in the treatment of rheumatoid arthritis and has shown promise in case studies for the treatment of severe SLE that is resistant to other treatments. This example raises the possibility that rituximab-induced B-cell depletion may offer a significant new therapeutic alternative for cases of this severe ocular consequence that are resistant to other treatments.
what is lupus erythematosus ?
Known as SLE, systemic lupus erythematosus is an autoimmune condition. In this illness, the body's immune system unintentionally targets healthy tissue for attack. The skin, joints, kidneys, brain, and other organs may be impacted.
What is retinal vasculitis?
Inflammatory eye disease that affects the retinal vessels is called retinal vaculitis. The clinical diagnosis of retinal vasculitis is made, and fundus fluorescein angiography is used to confirm it. Exudates surrounding retinal vessels that cause white sheathing or cuffing of the afflicted vessels are the hallmark of active vascular disease. Based on ophthalmoscopic and fundus fluorescein angiographic findings, a practical approach to the diagnosis of retinal vasculitis is addressed in this article.
what is rituximab therapy?
Non-lymphoma Hodgkin's is a kind of cancer that is treated with rituximab injection either alone or in combination with other medications (NHL). Additionally, it is used in conjunction with other cancer treatments to treat mature B-cell acute leukemia and non-Hodgkin lymphoma (NHL) (B-AL).
To know more about lupus visit:
https://brainly.com/question/4216674
#SPJ4
Thank you for participating in our discussion. We value every contribution. Keep sharing knowledge and helping others find the answers they need. Let's create a dynamic and informative learning environment together. IDNLearn.com is your go-to source for accurate answers. Thanks for stopping by, and come back for more helpful information.
